Lv7
3470 积分 2022-07-25 加入
Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
11个月前
已完结
Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer
11个月前
已完结
Trastuzumab deruxtecan for HER2+ advanced breast cancer
11个月前
已完结
Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
11个月前
已完结
Enema of Traditional Chinese Medicine for Patients with Severe Acute Pancreatitis
11个月前
已完结
A network meta-analysis on the efficacy of HER2-targeted agents in combination with taxane-containing regimens for treatment of HER2-positive metastatic breast cancer
1年前
已完结
HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials
1年前
已完结
Exposure–Response Relationship of T-DM1: Insight Into Dose Optimization for Patients With HER2-Positive Metastatic Breast Cancer
1年前
已完结
Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study
1年前
已完结
Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer
1年前
已完结
皖公网安备34019202002308
